Salivary duct carcinoma of the parotid gland presenting KIT (CD117) overexpression [1]

Histopathology

Volumn 51, Issue 1, 2007, Pages 114-115

  Sato, K ^a   Shimode, Y ^a   Itoi, A ^a   Ueda, Y ^a   Katsuda, S ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; STEM CELL FACTOR RECEPTOR;

ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTID GLAND CARCINOMA; PAROTIDECTOMY; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA;

ADENOCARCINOMA; AGED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PAROTID NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; SALIVARY DUCTS;

EID: 34250888305     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02709.x     Document Type: Letter

References (12)

1. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996 77 223 230.
2. Diallo R, Rody A, Jackisch C et al. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. Hum. Pathol. 2006 37 205 211.
3. Tsuda H, Morita D, Kimura M et al. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005 96 48 53.
4. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000 154 107 111.
5. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod. Pathol. 2003 16 1224 1231.
6. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002 20 1692 1703.
7. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol. Int. 2006 56 1 9.
8. Heinrich MC. Is KIT an important therapeutic target in small cell lung cancer? Clin. Cancer Res. 2003 9 5825 5828.
9. Johnson BE, Fischer T, Fischer B et al. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 2003 9 5880 5887.
10. Krug LM, Crapanzano JP, Azzoli CG et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005 103 2128 2131.
11. Rossi G, Cavazza A, Marchioni A et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod. Pathol. 2003 16 1041 1047.
12. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J. Clin. Oncol. 2005 23 585 590.